Shares of AstraZeneca jumped 8.54% to ₹7,324.25 in early trading after receiving approval from the Central Drugs Standard Control Organization (CDSO) for the import, sale, and distribution of Durvalumab, a key cancer treatment drug. This regulatory nod has driven strong investor sentiment, pushing the stock to an intraday high of ₹7,349.95.
Key Stock Price Details:
- Open: ₹6,900.00
- High: ₹7,349.95
- Low: ₹6,851.30
- Previous Close: ₹6,748.10
The approval is expected to boost AstraZeneca’s portfolio in the Indian market, enhancing its presence in the oncology segment. The news has triggered significant buying interest, propelling the stock upwards.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
